SAN DIEGO--(BW HealthWire)--April 18, 2002--Structural Bioinformatics Inc. (SBI), a leading proteomics-driven drug discovery company, announced today that it has expanded its research collaboration with Johnson & Johnson Pharmaceutical Research & Development L.L.C (PRD).
The collaboration was initiated in January 2001.
SBI will expand its structural proteomics services in support of PRD's drug discovery programs using X-ray crystallography and drug-protein co-crystallization technologies for PRD proprietary compounds. Financial terms were not disclosed.
``Access to 3D protein structures is playing an increasingly important role in boosting drug optimization research throughout the pharmaceutical industry'', said Edward T. Maggio, Ph.D., chairman and CEO of Structural Bioinformatics Inc. ``SBI's high-throughput, cost effective, structural proteomics technologies are applicable to the thousands of potential new drug targets emerging from genomic sequencing efforts.''
About Structural Bioinformatics Inc.
Structural Bioinformatics Inc. (SBI) is a world leader in proteomics-driven drug discovery -- the large-scale generation and use of protein structural information to accelerate the drug discovery and optimization processes. SBI's Genes to Leads® technology offers a practical response to the flood of new drug targets emerging from genomic sequencing efforts for the human genome and the genomes of hundreds of infectious disease agents. SBI's technology reliably produces drug leads -- in 60-120 days -- starting with the drug target sequence alone, with an efficiency that is more than 1,000-fold greater than state-of-the-art high throughput screening. SBI's proprietary computational proteomics platform produces major benefits in pharmaceutical development, speeding drug discovery, reducing costs and increasing the probability of success. SBI's drug discovery pipeline is focused on therapeutics for diabetes, cancer and inflammatory and infectious diseases. SBI further leverages its technologies to create a growing revenue stream through its StructureBank(TM) 3D protein structure database management system and its structural content products -- ProMax(TM) -- a comprehensive drug target database, and Variome(TM) -- individual drug target-specific structural pharmacogenomics database modules.
SBI has partnerships with a number of technology leaders in their respective industry segments, including Johnson & Johnson Pharmaceutical Research & Development, Boehringer Ingelheim, DuPont Pharmaceuticals, Yamanouchi Pharmaceuticals Ltd., IBM Life Sciences and Quest Diagnostics.
SBI is headquartered in San Diego with offices in Cambridge, Mass.; Washington, D.C.; and Hoersholm, Denmark. More information may be found on SBI's Web site at www.strubix.com |
